There are 17 papers on LGALS9 in aging research: 3 trials and 7 observational studies in people, 4 in animals, 1 review.
At a glance
The findings reach people, from one lab or study. 5 independent labs in 7 countries; 2 trials.
“changes in GAL9 and THBS2 were associated with spironolactone-induced PICP reduction, which was confirmed in Aldo-DHF patients”
None of its findings points the other way.
- 5 independent labs in 7 countries
- 2 trials
- Funders: National Key Research and Development Program of China and others
- 2 of 6 findings with company ties
- 2 of 2 trials sponsored by developers of drugs aimed at it
- Human trial3
- Humans7
- Animals4
- In silico2
Effects
2Inflammation
upin mice1
1 study
Inflammation
upin mice1
LGALS9 increases inflammation in mice (shown by knockout in APP/PS1 mice).
Animalsshown by knockout in APP/PS1 micebrain
Aβ sedimentation
upin mice1
1 study
Aβ sedimentation
upin mice1
LGALS9 increases Aβ sedimentation in mice (shown by knockout in APP/PS1 mice).
Animalsshown by knockout in APP/PS1 micebrain
Upstream
1Cellular senescence
upin humans1
1 study
Cellular senescence
upin humans1
Cellular senescence is linked with higher LGALS9 in humans (IUA endometrium).
HumansIUA endometriumendometrium
Associations
3Systolic blood pressure
upin humans1
1 study
Systolic blood pressure
upin humans1
LGALS9 is associated with systolic blood pressure in humans (β=9.73).
Humanswhole blood
PICP
downin humans1
1 study
PICP
downin humans1
LGALS9 is associated with PICP in humans (associated with spironolactone-induced PICP reduction).
Human trialassociated with spironolactone-induced PICP reduction
Brain age gap
upin humans1
1 study
Brain age gap
upin humans1
LGALS9 is associated with brain age gap in humans.
Human trialserum